Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty

American Journal of Cardiology

Volumn 83, Issue 11, 1999, Pages 1524-1529

  Gimple, Lawrence W ^a   Herrmann, Howard C ^b   Winniford, Michael ^c   Mammen, Eberhard ^d  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEMATOCRIT; HEPARINIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; ST SEGMENT DEPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREADMILL EXERCISE; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES; CORONARY DISEASE; DOUBLE-BLIND METHOD; EXERCISE TEST; FACTOR XA; HEMATOCRIT; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PLATELET COUNT; TREATMENT OUTCOME;

EID: 0033152358     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00141-1     Document Type: Article

References (21)

1. Guyton J.R., Rosenberg R.D., Clowes A.W., Karnovsky M.J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 46:1980;625-634.
2. Clowes A.W., Karnowsky M.J. Supression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 265:1977;625-626.
3. Castellot J.J. Jr, Beeler D.L., Rosenberg R.D., Karnovsky M.J. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol. 120:1984;315-320.
4. McNamara C.A., Sarembock I.J., Gimple L.W., Fenton J.W. II, Coughlin S.R., Owens G.K. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 91:1993;94-98.
5. Troy S., Fruncillo R., Ozawa T., Mammen E., Holloway S., Chiang S. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. Thromb Haemost. 78:1997;871-875.
6. Troy S., Fruncillo R., Ozawa T., Mammen E., Holloway S., Chiang S. The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers. J Clin Pharmacol. 35:1995;1194-1199.
7. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
8. Amann F.W., Neuenschwander C., Meyer B.J. Fraxiparin for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost. 19:(suppl 1):1993;160-163.
9. Cairns J.A., Gill J., Morton B., Roberts R., Gent M., Hirsh J., Holder D., Finnie K., Marquis J.F., Naqvi S., Cohen E. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation. 94:1996;1553-1560.
10. Karsch K.R., Preisack M.B., Baildon R., Eschenfelder V., Foley D., Garcia E.J., Kaltenbach M., Meisner C., Selbmann H.K., Serruys P.W., Shiu M.F., Sujatta M., Bonan R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol. 28:1996;1437-1443.
11. Faxon D.P., Spiro T.E., Minor S., Cote G., Douglas J., Gottlieb R., Califf R., Dorosti K., Topol E., Gordon J.P., Ohmen M. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation. 90:1994;908-914.
12. Ozawa T., Mammen E.F. LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL). Thromb Res. 66:1992;287-298.
13. Ellis S.G., Roubin G.S., Wilentz J., Douglas J.S. Jr, King S.B. III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 117:1989;777-782.
14. Brack M.J., Ray S., Chauhan A., Fox J., Hubner P.J., Schofield P., Harley A., Gershlick A.H. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J Am Coll Cardiol. 26:1995;947-954.
15. Lablanche J.M., McFadden E.P., Meneveau N., Lusson J.R., Bertrand B., Metzger J.P., Legrand V., Grollier G., Macaya C., de Bruyne B., Vahanian A., Grentzinger A., Masquet C., Wolf J.E., Tobelem G., Fontecave S., Vacheron A., d'Azemar P., Bertrand M.E. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty the FACT study. Fraxiparine Angioplastie Coronaire Transluminale . Circulation. 96:1997;3396-3402.
16. Anonymous. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 330:1994;956-961.
17. Kimura T., Kaburagi S., Tamura T., Yokoi H., Nakagawa Y., Hamasaki N., Nosaka H., Nobuyoshi M., Mintz G.S., Popma J.J., Leon M.B. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation. 96:1997;475-483.
18. Mintz G.S., Kent K.M., Pichard A.D., Satler L.F., Popma J.J., Leon M.B. Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Circulation. 95:1997;1791-1798.
19. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P., Belardi J., Sigwart U., Colombo A., Goy J.J., Van den Heuvel P., Delcan J., Morel M.-A. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 331:1994;489-495.
20. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M., Cleman M., Heuser R., Almond D., Teirstein P.S., Fish R.D., Colombo A., Brinker J., Moses J., Shaknovich A., Hirshfeld J., Bailey S., Ellis S., Rake R., Goldberg S. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 331:1994;496-501.
21. Teirstein P.S., Massullo V., Jani S., Popma J.J., Mintz G.S., Russo R.J., Schatz R.A., Guarneri E.M., Steuterman S., Morris N.B., Leon M.B., Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 336:1997;1697-1703.